Drug development and commercialization for gastroenterology and urological diseases
Oceana was a specialty pharmaceuticals company focusing on inlicensing, developing, and commercializing therapeutics for gastroenterology and urological diseases. The company's portfolio included the following products: 1) Deflux, a commercial-stage bulking agent indicated for treatment of children with vesicoureteral reflux; and 2) Solesta, a biocompatible bulking gel for treatment of fecal incontinence. Oceana received FDA approval for Solesta in 2011, and the company was subsequently acquired by Salix the same year.